J
Joseph J. Eron
Researcher at University of North Carolina at Chapel Hill
Publications - 569
Citations - 49427
Joseph J. Eron is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Viral load & Population. The author has an hindex of 99, co-authored 511 publications receiving 44857 citations. Previous affiliations of Joseph J. Eron include Duke University.
Papers
More filters
Posted ContentDOI
Molnupiravir, an Oral Antiviral Treatment for COVID-19
William A. Fischer,Joseph J. Eron,Wayne Holman,Myron S. Cohen,Lei Fang,Laura J. Szewczyk,Timothy P. Sheahan,Ralph S. Baric,Katie R. Mollan,Cameron R. Wolfe,Elizabeth R. Duke,Masoud M Azizad,Katyna BorrotoiEsoda,David A. Wohl,Amy James Loftis,Paul Alabanza,Felicia Lipansky,Wendy Painter +17 more
TL;DR: In this paper, the safety, tolerability, and antiviral efficacy of molnupiravir in the treatment of COVID-19 were evaluated in a Phase 2a trial.
Journal ArticleDOI
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
Jacob Lalezari,Joseph J. Eron,Margrit Carlson,Calvin J. Cohen,Edwin DeJesus,Roberto C. Arduino,Joel E. Gallant,Paul A. Volberding,Robert L. Murphy,Fred T. Valentine,Emily L. Nelson,Prakash R. Sista,Alex Dusek,J. Michael Kilby +13 more
TL;DR: Self-administration of enfuvirtide is not associated with unexpected toxicities for up to one year, and combined with oral antiretroviral drugs was associated with a significant decrease in HIV RNA and an increase in CD4 cell counts.
Journal ArticleDOI
Frequent detection of acute primary HIV infection in men in Malawi
Christopher D. Pilcher,Matthew Price,Irving F. Hoffman,Shannon Galvin,Francis Martinson,Peter N. Kazembe,Joseph J. Eron,William C. Miller,Susan A. Fiscus,Myron S. Cohen +9 more
TL;DR: Traditional HIV antibody tests alone are not sufficient to exclude HIV infection among men with acute STD in Malawi due to a surprising proportion of acute HIV infections in this population.
Journal ArticleDOI
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
Huldrych F. Günthard,Huldrych F. Günthard,Diane V. Havlir,Susan A. Fiscus,Zhiqiang Zhang,Joseph J. Eron,John W. Mellors,Roy M. Gulick,Simon D. W. Frost,Andrew J. Leigh Brown,William A. Schleif,Fred T. Valentine,Leslie Jonas,Anne R. Meibohm,Caroline Ignacio,Robin Isaacs,Reza A. Gamagami,Emilio A. Emini,Ashley T. Haase,Douglas D. Richman,Douglas D. Richman,Joseph K. Wong,Joseph K. Wong +22 more
TL;DR: In patients receiving potent antiretroviral therapy, the greatest virus burden may continue to be in lymphoid tissues rather than in central nervous system or genitourinary compartments.
Journal ArticleDOI
Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients
Constance A. Benson,Steven G. Deeks,Scott C. Brun,Roy M. Gulick,Joseph J. Eron,Harold A. Kessler,Robert L. Murphy,Charles B. Hicks,Martin S. King,David Wheeler,Judith Feinberg,Richard Stryker,Paul E. Sax,Sharon A. Riddler,Melanie A. Thompson,Kathryn Real,Ann Hsu,Dale J. Kempf,Anthony J. Japour,Eugene Sun +19 more
TL;DR: The safety and antiviral activity of lopinavir (Lpv), a protease inhibitor (PI) coformulated with ritonavir (Rtv) to enhance its pharmacokinetic properties, were evaluated in 70 patients with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels of 1000-100,000 copies/mL on a first PI-containing regimen.